EARLY WARNING NEWS RELEASE OF ANDREW BENEDEK PROVIDING UPDATE TO OPTION AGREEMENT WITH ANDREW MARNY S. A.

NORTH SAANICH, BC, Sept. 30, 2026 /CNW/ — On August 11, 2026, Dr. Andrew Benedek (“Benedek“) announced that he had entered into share option agreement with Marny S.A. (“Marny“)  dated August 11, 2026 (the “Option Agreement“) pursuant to which Benedek granted to Marny an option (the “Option“), subject to certain terms and conditions, to acquire up to 32,988,232 of the common shares (the “Shares“) of Anaergia Inc. (“Anaergia“) (such Shares subject to the Option, the “Optioned Shares“) at a price of C$3.00 per Share.

In accordance with the terms of the Option Agreement, the term of the Option has been automatically extended until the earlier of (i) five business days after the date on which the Company’s interim financial statements and management’s discussion and analysis for the period ended September 30, 2026, are filed on SEDAR+, and (ii) November 20, 2026. All other terms and conditions of the Option Agreement remain as previously disclosed on the August 11, 2026, press release and early warning report.

As of the date of this press release, Benedek has ownership or control over (i) 32,988,232 Shares, representing approximately 19.2% of the issued and outstanding Shares on a non-diluted basis and (ii) 61,324 RSUs. If the Option is exercised in full and assuming conversion of all of his RSUs into Shares, Benedek would have ownership or control over 61,324 Shares, representing 0.04% of the issued and outstanding Shares, on a partially diluted basis. 

As previously disclosed in the August 11, 2026, Benedek’s press release and early warning report, if and to the extent that the Option is exercised, Benedek will be disposing of those Optioned Shares which are acquired by Marny to liquidate some or all of his investment in Anaergia. If and to the extent that Marny does not acquire some or any of the Optioned Shares, Benedek may retain such unsold Shares for investment purposes or may dispose of some or all of such Shares from time to time.

Benedek currently has no plans or intentions that relate to or would result in any of the actions listed in items (a) to (k) of Item 5 in the early warning reports filed by Benedek in connection with the Option Agreement (the “Early Warning Report“). However, depending on market conditions, general economic and industry conditions, trading prices of Anaergia’s securities, Anaergia’s business, financial condition and prospects, and/or other relevant factors, Benedek may develop such plans or intentions in the future.

The head office of Anaergia is located at 4210 South Service Road, Burlington, Ontario L7L 4X5.

For further information, please refer to the Early Warning Reports that are to be posted on the SEDAR+ profile of Anaergia at www.sedarplus.ca, or that may be obtained from:

Andrew Benedek

470 Land’s End Road

North Saanich, B.C.  V8L 5L9

760-815-6939

SOURCE Dr. Andrew Benedek